Overview
ReiThera is an Italian CDMO specializing in process development and GMP manufacturing of viral vectors including AAV, Ad (GRAd platform), MVA, HSV, and LVV for gene therapies and vaccines. The company operates a state-of-the-art facility in Rome with bioreactors up to 2000-3000L scale, fixed-bed systems, fill/finish suites, and quality control labs, supporting end-to-end services from vector design to commercial production. Key platforms include ReiCell-AAV for scalable AAV production and validated MVA processes.
Frequently asked questions
- What viral vectors does ReiThera manufacture?
- ReiThera specializes in AAV, adenoviral vectors (GRAd platform), MVA, HSV, and lentiviral vectors (LVV) for gene therapies and vaccines.
- What are ReiThera's manufacturing capabilities and scales?
- The Rome facility features bioreactors from 2L to 2000-3000L, fixed-bed systems, four independent GMP suites, fill/finish, and QC labs for clinical and commercial production.
- Does ReiThera support full development to commercialization?
- Yes, ReiThera provides end-to-end CDMO services from vector design and process development through GMP manufacturing and immunomonitoring for gene therapy and vaccine programs.